ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
UK NICE recommends Kyowa Kirin’s Poteligeo for rare blood cancers
November 12, 2021The UK National Institute for Health and Care Excellence (NICE) has recommended Kyowa Kirin’s humanised monoclonal antibody, Poteligeo (mogamulizumab), to treat adult patients... -
Kyowa Kirin: New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients
June 11, 2021Kyowa Kirin today announced a new analysis of data showing statistically significant improvements in quality of life in cutaneous T-cell lymphoma (CTCL) patients treated with mogamulizumab with blood involvement, compared to vorinostat.
Pharma Sources Insight January 2025
